India's drug industry faces $570.7M hit from fixed-dose ban

India's domestic drug market could see an INR38 billion ($570.7 million) hit from a ban on more than 300 fixed-dose drugs that combine therapies often without new clinical trials in a widely used method that has formulations running into the thousands, many of which are approved at the state level. The Economic Times said the move has taken the pharmaceutical industry by surprise with domestic firms as well as Indian units of multinationals such as Pfizer ($PFE) and Abbott Laboratories ($ABT) seeking to appeal the decisions through court filings. A separate report by the Economic Times said India's Ministry of Health is examining as many as 1,700 more fixed dose products for safety. Report

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.